Business Context and Reporting Period
Company: InfuSystem Holdings, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: InfuSystem is the leading provider of infusion pumps and related services, primarily supplying electronic ambulatory infusion pumps and disposable kits to oncology practices for colorectal cancer treatment. The company retains title to the pumps and bills insurance providers directly. In June 2010, the company acquired First Biomedical, Inc., expanding its capabilities in biomedical service, repair, and sales of medical equipment to alternate site healthcare facilities.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Net Revenues | $47.2 million | $39.0 million |
| Gross Profit | $33.5 million | $28.6 million |
| Gross Margin | 71% | 73% |
| Net (Loss) Income | $(1.9) million | $0.8 million |
| Operating Cash Flow | $10.8 million | $9.7 million |
| Cash and Equivalents | $5.0 million | $7.8 million |
| Total Debt (Long-term + Current) | $32.2 million | $24.1 million |
| Stockholders' Equity | $85.1 million | $81.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 21% to $47.2 million, driven primarily by the acquisition of First Biomedical and deeper penetration into existing customer facilities.
- Profitability Decline: The company reported a net loss of $1.9 million in 2010 compared to a net income of $0.8 million in 2009. This was due to a significant increase in General and Administrative (G&A) expenses, which rose from $12.2 million to $20.6 million (44% of revenue vs. 31% in 2009), largely due to share-based compensation and acquisition-related costs.
- Debt Restructuring: In June 2010, the company entered a new credit facility with Bank of America consisting of a $30 million term loan and a $5 million revolving credit facility, replacing prior debt held by Kimberly-Clark (I-Flow).
- Acquisition Impact: The acquisition of First Biomedical for $17.4 million added significant intangible assets and goodwill, increasing amortization expenses by 28% year-over-year.
Guidance, Outlook, and Risks
Outlook and Strategy: Management plans to expand into treatments for cancers other than colorectal (e.g., head and neck, pancreatic) and pursue further strategic acquisitions. The company believes its established network of over 1,300 oncology practices and contracts covering 195 million lives provide competitive barriers.
Key Risks:
- Reimbursement Dependency: Revenue is heavily dependent on third-party reimbursement rates. Medicare accounts for approximately 31% of gross billings. Changes in reimbursement policies or rates could materially impact financial results.
- Regulatory Compliance: The company relies on its Medicare Supplier Number and accreditation (CHAP) to operate. Loss of accreditation or non-compliance with DMEPOS standards would prevent billing Medicare.
- Market Competition: The industry is competitive with regional providers, hospital-owned DME providers, and home care infusion providers.
- Goodwill Impairment: The company performed an annual goodwill impairment test in October 2010 with no impairment found, but noted that fair value exceeded carrying value by less than 10%. Future declines in market capitalization or operational performance could trigger impairment charges.
Investor Verification Checklist
- Reimbursement Rates: Verify current and projected reimbursement rates from Medicare and major commercial payors (Blue Cross/Blue Shield) to assess revenue stability.
- Debt Covenants: Review compliance with the new Bank of America credit facility covenants, specifically the total leverage ratio and fixed charge coverage ratio.
- Share-Based Compensation: Analyze the sustainability of G&A expenses, noting the significant increase in stock-based compensation ($5.9 million in 2010 vs. $0.8 million in 2009).
- Goodwill Valuation: Monitor the company's market capitalization relative to its net asset carrying value, given the narrow margin in the 2010 impairment test.
- Acquisition Integration: Assess the realization of synergies and cost savings from the First Biomedical acquisition to offset increased operating expenses.